179) ontributing fundamentally to the COVID-19 response. |
180) cally linked to ketamine's antidepressant response. |
181) slowly without causing a systemic immune response. |
182) ions as a cytokine to modulate the immune response. |
183) function in GC B cells to sustain the GC response. |
184) s arrive at these states during an immune response. |
185) not be able to mount an effective immune response. |
186) or affecting the enzyme activity and drug response. |
187) o initiate an antiviral type I interferon response. |
188) xpression profiles indicative of a recall response. |
189) evels of mutations and/or an inflammatory response. |
190) and play a crucial role in shaping immune response. |
191) o the initiation of the immunotherapeutic response. |
192) ty would serve as a mediator of treatment response. |
193) re coordinated economic and public health response. |
194) hence, immune checkpoint inhibitor (ICI) response. |
195) ole in iron transport and in inflammatory response. |
196) atin intolerance on the outcome of statin response. |
197) medicine in the prediction of vaccination response. |
198) a biomarker of the systemic inflammatory response. |
199) decision model for a four-activity level response. |
200) ed in the absence of a problem-indicative response. |
201) recipient, and iii) evoke a donor immune response. |
202) will unleash the secondary anti-viral IFN response. |
203) contribute to variability in montelukast response. |
204) %) patients achieved marrow U-MRD as best response. |
205) ch are integral to cellular innate immune response. |
206) lear cell signatures also correlated with response. |
207) n to their fundamental role in the stress response. |
208) and bacterial adhesion, and evades immune response. |
209) ined by emerging predictive biomarkers of response. |
210) erapies to combat this hyper-inflammatory response. |
211) ironments to regulate the cellular immune response. |
|